thalidomide has been researched along with Vitiligo in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo." | 9.34 | Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study. ( Fontas, E; Khemis, A; Lacour, JP; Montaudié, H; Moulin, S; Passeron, T, 2020) |
| "Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo." | 5.34 | Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study. ( Fontas, E; Khemis, A; Lacour, JP; Montaudié, H; Moulin, S; Passeron, T, 2020) |
| "Leprosy and vitiligo are common affections in the West Indies." | 1.31 | High prevalence of vitiligo in lepromatous leprosy. ( Boisseau-Garsaud, AM; Garsaud, P; Helenon, R; Quist, D; Saint-Cyr, I; Vezon, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Plachouri, KM | 1 |
| Kyriakou, G | 1 |
| Chourdakis, V | 1 |
| Georgiou, S | 1 |
| Grafanaki, K | 1 |
| Khemis, A | 1 |
| Fontas, E | 1 |
| Moulin, S | 1 |
| Montaudié, H | 1 |
| Lacour, JP | 1 |
| Passeron, T | 2 |
| Ezzedine, K | 1 |
| Vance, TM | 1 |
| Hamzavi, IH | 1 |
| Qureshi, AA | 1 |
| Kim, HJ | 1 |
| Singer, GK | 1 |
| Del Duca, E | 1 |
| Abittan, BJ | 1 |
| Chima, MA | 1 |
| Kimmel, G | 1 |
| Bares, J | 1 |
| Gagliotti, M | 1 |
| Genece, J | 1 |
| Chu, J | 1 |
| Wilding, G | 1 |
| Pavel, AB | 1 |
| Guttman-Yassky, E | 1 |
| Lebwohl, MG | 1 |
| Majid, I | 1 |
| Imran, S | 1 |
| Batool, S | 1 |
| Boisseau-Garsaud, AM | 1 |
| Vezon, G | 1 |
| Helenon, R | 1 |
| Garsaud, P | 1 |
| Saint-Cyr, I | 1 |
| Quist, D | 1 |
| Frank, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO[NCT03036995] | Phase 2 | 80 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Vitiligo
| Article | Year |
|---|---|
One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Early Diagnosis; Humans; Male; Middle Aged; Prognosis; Psor | 2019 |
[What's new in dermatological research?].
Topics: Biomedical Research; Dermatitis, Atopic; Dermatology; Herpesviridae Infections; HIV Infections; Huma | 2010 |
2 trials available for thalidomide and Vitiligo
| Article | Year |
|---|---|
Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Dou | 2020 |
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.
Topics: Humans; Pilot Projects; Skin Pigmentation; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Viti | 2021 |
4 other studies available for thalidomide and Vitiligo
| Article | Year |
|---|---|
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.
Topics: Humans; Prospective Studies; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2020 |
Apremilast is effective in controlling the progression of adult vitiligo: A case series.
Topics: Adult; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Thalidomide; Vitiligo | 2019 |
High prevalence of vitiligo in lepromatous leprosy.
Topics: Adult; Aged; Aged, 80 and over; Clofazimine; Dapsone; Female; Humans; Leprostatic Agents; Leprosy, L | 2000 |
Scleroderma.
Topics: Alopecia Areata; Azathioprine; Biopsy; Bursitis; Colchicine; Diagnosis, Differential; Drug Therapy, | 2001 |